Study of LN-145 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck



Status:Recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/5/2019
Start Date:January 9, 2017
End Date:June 2022
Contact:Iovance Biotherapeutics Study Team
Email:Clinical.Inquiries@iovance.com
Phone:866-565-4410

Use our guide to learn which trials are right for you!

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) for the Treatment of Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Prospective, multicenter, single-arm, open label, interventional study evaluating adoptive
cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145)
followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the
treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head
and neck

LN-145 is an adoptive cell transfer therapy that utilizes an autologous TIL manufacturing
process, as originally developed by the NCI, for the treatment of patients with recurrent
and/or metastatic squamous cell carcinoma of the head and neck. The cell transfer therapy
used in this study involves patients receiving a NMA lymphocyte depleting preparative
regimen, followed by infusion of autologous TIL followed by the administration of a regimen
of IL-2.

Inclusion Criteria

- Must be greater than 18 years of age at the time of consent.

- Must have recurrent and/or metastatic, squamous cell carcinoma of the head and neck
(both HPV-positive and -negative)

- Must have at least 1 lesion that is resectable for TIL generation.

- Must have measurable disease as defined by RECIST v1.1 following the surgical
resection.

- Must have received at least 1 and no more than 3 lines of prior systemic immunotherapy
and/or chemotherapeutic treatments for HNSCC.

- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

- Patients must be seronegative for the HIV antibody.

- Patients seropositive for hepatitis B virus surface antigen (HBsAg), hepatitis B core
antibody (anti-HBc), or hepatitis C virus (anti-HCV) indicating acute or chronic
infection may be enrolled if the viral load by polymerase chain reaction (PCR) is
undetectable with/without active treatment

- Male and female patients of childbearing potential must be willing to practice an
approved method of birth control starting at the time of informed consent and for 1
year after the completion of the study treatment regimen.

Exclusion Criteria:

- Patients who have received an organ allograft or prior cell transfer therapy, except
for prior LN-145.

- Patients who are on a systemic steroid therapy (greater than 10 mg of prednisone or
equivalent). A short course of higher dose steroid therapy is allowed.

- Patients who currently have prior therapy-related toxicities greater than Grade 1
according to Common Toxicity Criteria for Adverse Events (CTCAE) v4.03; except for
neuropathy, dysphagia, alopecia or vitiligo prior to tumor resection.

- Patients with documented Grade 2 or greater diarrhea or colitis as a result of
previous immunotherapy within six months from screening.

- Patients who have a contraindication to or history of hypersensitivity reaction to
cyclophosphamide, mesna, fludarabine, IL-2, antibiotics of the aminoglycoside group,
any component of the TIL infusion product formulation including dimethylsulfoxide
(DMSO), human serum albumin (HSA), IL-2, and dextran-40.

- Patients with active systemic infections, coagulation disorders or other active major
medical illnesses of the cardiovascular, respiratory or immune system.

- Patients with symptomatic and/or untreated brain metastases.

- Have any form of primary or acquired immunodeficiency syndrome, such as severe
combined immunodeficiency disease or acquired immune deficiency syndrome (AIDS).

- Diagnosis of end-stage renal disease requiring hemodialysis.

- Patients who have a left ventricular ejection fraction (LVEF) < 45% or who are New
York Heart Association (NYHA) Class 2 or higher.

- Patients who have a forced expiratory volume in one second (FEV1) of less than 60% of
predicted normal; or walk a distance less than 80% predicted in a 6-minute walk test
or demonstrate evidence of hypoxia at any point during the test.

- Patients who have had another primary malignancy within the previous 3 years.

- Patients who are pregnant, parturient, or breastfeeding women.

- Patients who have received a live or attenuated vaccine within 28 days of the NMA-LD
regimen.

- Patients whose cancer requires immediate treatment or who would otherwise suffer a
disadvantage by participating in this study.
We found this trial at
19
sites
Los Angeles, California 90033
213) 740-2311
University of Southern California The University of Southern California is one of the world’s leading...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
3550 Jerome Avenue
Bronx, New York 10467
(718) 920-4321
Montefiore Medical Center As the academic medical center and University Hospital for Albert Einstein College...
?
mi
from
Bronx, NY
Click here to add this to my saved trials
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
4100 John R
Detroit, Michigan 48201
800-527-6266
Barbara Ann Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Seattle, Washington 98104
(206) 543-2100
Univ of Washington Founded in 1861 by a private gift of 10 acres in what...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Aurora, Colorado 80045
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Birmingham, Alabama 35294
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
(919) 962-2211
Univ of North Carolina Carolina’s vibrant people and programs attest to the University’s long-standing place...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
?
mi
from
Chicago, IL
Click here to add this to my saved trials
9500 Gilman Dr
La Jolla, California 92093
(858) 534-2230
The University of California, San Diego UC San Diego is an academic powerhouse and economic...
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
500 S Preston St
Louisville, Kentucky
(502) 852-5555
University of Louisville The University of Louisville is a state supported research university located in...
?
mi
from
Louisville, KY
Click here to add this to my saved trials
8701 W Watertown Plank Rd
Milwaukee, Wisconsin
(414) 955-8296
Medical College of Wisconsin The Medical College (MCW) of Wisconsin is a major national research...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Morristown, New Jersey 07962
?
mi
from
Morristown, NJ
Click here to add this to my saved trials
New Brunswick, New Jersey 08901
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15232
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
?
mi
from
Portland, OR
Click here to add this to my saved trials
Tampa, Florida 33612
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Westwood, Kansas 66205
?
mi
from
Westwood, KS
Click here to add this to my saved trials